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Abstract
Background: The prevalence of prescription opioid use among drivers has increased markedly in the past two
decades. The purpose of this study is to assess the associations of prescription opioid use and alcohol use with the
risk of fatal crash involvement in US drivers.
Methods: We performed a population-based case-control study using toxicological testing data from two national
data systems. Cases (n = 3606) were drivers involved in fatal motor vehicle crashes selected from the Fatality Analysis
Reporting System and controls (n = 15,600) were drivers participating in the 2007 and 2013 National Roadside Surveys
of Alcohol and Drug Use by Drivers. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95%
confidence intervals (95% CIs) of fatal crash involvement associated with prescription opioid use with and without the
presence of alcohol.
Results: Overall, cases were significantly more likely than controls to test positive for prescription opioids (5.0% vs.
3.7%, p < 0.001), alcohol (56.2% vs. 7.1%, p < 0.0001), and both substances (2.2% vs. 0.2%, p < 0.001). Relative to drivers
testing negative for prescription opioids and alcohol, the adjusted ORs of fatal crash involvement were 1.72 (95% CI:
1.37, 2.17) for those testing positive for prescription opioids and negative for alcohol, 17.92 (95% CI: 16.19, 19.84) for
those testing positive for alcohol and negative for prescription opioids, and 21.89 (95% CI: 14.38, 33.32) for those testing
positive for both substances. The interaction effect on fatal crash risk of prescription opioid use and alcohol use was not
statistically significant on either additive or multiplicative scale.
Conclusions: Prescription opioid use is associated with a significantly increased risk of fatal crash involvement
independently of alcohol use. Concurrent use of prescription opioids and alcohol is associated with a 21-fold increased
risk of fatal crash involvement.
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Background
Prescription opioids, such as oxycodone and hydrocodone,
are widely used in pain management and as anesthetics in
surgery (Manchikanti and Singh 2008; Han et al. 2017;
Governor’s Highway Safety Association (GHSA), 2018). In
2015, nearly 92 million US adults (about 38% of the total
adult population) reported taking a legitimately prescribed
opioid (Han et al. 2017). In light of unabated increases in
drug overdose mortality, the US federal government de-
clared the opioid epidemic a national public health emer-
gency in October 2017. Although the opioid epidemic is
viewed primarily through counts of overdose fatalities, its
impact on driving safety has become a cause of concern.
Motor vehicle crashes are the second leading cause of un-
intentional injury mortality, and death rates per 100 mil-
lion vehicle miles traveled have increased 2.6% from 2015
to 2016 following a long downward trend (National Cen-
ter for Injury Prevention and Control 2016; National
Highway Traffic Safety Administration 2017). While an-
nual prescriptions of opioids have decreased from 277
million in 2012 to 239 million in 2016, the prevalence of
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prescription opioids detected among fatally injured drivers
continues to rise (Brady and Li 2012; Pezalla et al. 2017;
Chihuri and Li 2017a; Faryar et al. 2018). In 2016, 10.7%
of all fatally injured drivers tested positive for prescription
opioids, representing a 10-fold increase since 1995 (Chi-
huri and Li 2017a; Governor’s Highway Safety Association
(GHSA), 2018).
Use of prescription opioids may impair psychomotor
and cognitive skills necessary for safe operation of a motor
vehicle, such as manual dexterity, hand-eye coordination,
mental alertness, and visual information processing (Of-
fice of National Drug Control Policy 2011; Dowell et al.
2016; Ferreira et al. 2018). While results of experimental
studies examining the effects of prescription opioid use on
driving performance are inconsistent (Lenné et al., 2000;
Fishbain et al. 2003; Kress and Kraft 2005; Borgeat 2010;
Leung 2011; Strand et al. 2016; Strand et al. 2017), it is
evident that drivers on prescription opioids tend to show
decreased visual information processing speed and accur-
acy (Gaertner et al. 2006; Byas-Smith et al. 2005;
Mailis-Gagnon et al. 2012). Similarly, findings from epi-
demiological studies are conflicting, with most studies
reporting significantly increased risks of crash involve-
ment and crash culpability associated with prescription
opioid use (Bruera et al. 1989; Monárrez-Espino et al.,
2013; Gjerde et al. 2015; Rudisill et al. 2016; Chihuri and
Li 2017b, 2019) and others reporting no evidence of in-
creased risk (Bachs et al. 2009; Ray et al., 1992; Sims et al.,
1998; Dussault et al., 2002). These inconsistences are likely
caused in part by the increasing prevalence of prescription
opioid use in drivers and differences in research methods
and study populations. For example, some studies in-
cluded only younger drivers (Orriols et al. 2009), or only
older drivers (Marquet et al. 1998), while other studies
were restricted largely to male drivers (Monárrez-Espino
et al., 2016) or apparently underpowered (Christensen et
al. 1990). Polydrug use involving prescription opioids
and the interaction of alcohol and prescription opioids
are of increasing concern given that over 20% of fatally
injured drivers test positive for two or more drugs
(Movig et al. 2004; Drummer et al. 2004). The purpose
of this study is to assess the associations of prescription




We used data from two national surveillance systems
maintained by the National Highway Traffic Safety Ad-
ministration (NHTSA, Washington, DC): 1) the Fatality
Analysis Reporting System (FARS) and 2) the 2007 and
2013–14 National Roadside Survey of Alcohol and Drug
Use by Drivers (NRS). FARS is an annual census of
motor vehicle crashes occurring on US public roadways
that result in at least one fatality within 30 days in all 50
states, the District of Columbia and Puerto Rico (Li et
al. 2013; National Highway Traffic Safety Administration
2016). For each crash, the FARS records detailed data on
crash circumstances (e.g., date, time, road and weather
conditions), individuals involved (e.g., driver, passenger,
pedestrian, and cyclist), driver characteristics (e.g., age,
sex, race, drug testing results, driving history within the
previous 3 years, survival status) and vehicle characteris-
tics (e.g., vehicle type, make, model and year). Data in
the FARS come from multiple sources, including the
coroner or medical examiners’ reports, state highway pa-
trol records, police accident reports, death certificates,
medical records and vehicle registration files. Analysts
improve the accuracy and completeness of data through
automatic checks of each entry and other rigorous qual-
ity control programs. Although FARS was incepted in
1975, collection of toxicological testing data for nonalco-
hol drugs started in 1991 (National Highway Traffic
Safety Administration 2016).
The 2007 and 2013–14 NRSs were national field
surveys to estimate the prevalence of alcohol and drug
use in the driver population. The surveys involved ran-
domly stopped and verbally consented non-commercial
drivers at 300 locations across the continental United
States (Lacey et al. 2009; National Highway Traffic
Safety Administration 2010a; Kelley-Baker et al. 2016).
Drivers were selected through a four-stage stratified ran-
dom sampling scheme based on primary sampling units,
police jurisdictions, survey locations and passing-by
drivers. Drivers who passed through designated locations
were randomly stopped and invited to participate in the
surveys. Commercial vehicle drivers, drivers under the
age of 16, and drivers who could not communicate in
English or Spanish were excluded from the surveys. Eli-
gible drivers who voluntarily participated in the surveys
were asked to provide an oral fluid sample for drug test-
ing and a breath sample for alcohol testing. Participating
drivers also provided additional information on demo-
graphic characteristics, self-reported drinking and drug
use behavior, mileage and trip origin and destination.
Both the 2007 and 2013–14 NRS surveys were con-
ducted from 9:30 am to 11:30 am and 1:30 pm to 3:30
pm on Fridays and from 10 pm to midnight and 1 am to
3 am on both Friday and Saturday nights. The 2007 sur-
vey was conducted from July 20 through December
12, 2007 and the 2013–14 survey from June 7, 2013
through March 30, 2014. Of the 22,009 eligible drivers
(10,909 for the 2007 NRS and 11,100 for 20013–14
NRS), 15,600 (70.9%; 70.8% for the 2007 NRS and 71.0%
for the 2013–14 NRS) completed the interview and pro-
vided an oral fluid sample for drug testing (including
7905 drivers who also provided a blood sample). The
sampling methods and study protocols for the 2007 and
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2013–14 NRSs were described in detail elsewhere (Lacey
et al. 2009; Kelley-Baker et al. 2016).
Study design
We used a population-based case-control study design
to assess the individual and joint effects of prescription
opioid use and alcohol use on the risk of motor vehicle
crash involvement. Of the 6783 eligible cases, 3177
(46.8%) were excluded from the analysis because of
missing toxicological testing data [including 262 drivers
involved in fatal crashes in Maryland, New Mexico, and
North Carolina due to unreliable drug testing data re-
corded in the FARS from these states (Drummer et al.
2004; Brady and Li 2012; Chen et al. 2018)]. Conse-
quently, cases included in the study were 3606 drivers
who were involved in fatal motor vehicle crashes at spe-
cific times from 2006 to 2008 and from 2012 to 2014
and for whom toxicological testing data were available.
Controls included in the study were 15,600 drivers who
participated in the 2007 NRS or the 2013–14 NRS.
Cases and controls were matched on time of day, day of
week, and month of year (i.e., from 9:30 am to 11:30 am
and 1:30 pm to 3:30 pm on Fridays and from 10 pm to
midnight and 1 am to 3 am on both Friday and Saturday
nights). The Columbia University Irving Medical Center
Institutional Review Board (New York, NY) deemed this
study exempt from review under 45 CFR 46.
Drug testing assessments
Toxicological tests for cases were based on blood and/or
urine specimens through radioimmunoassay techniques
and liquid/gas chromatography combined with mass
spectrometry (Li et al. 2013; Kelley-Baker et al. 2016). Of
all cases, 3247 (90.0%) had at least one drug test based
on blood specimens. For each case, up to 3 nonalcohol
drugs were recorded in the FARS. When multiple nonal-
cohol drugs were detected, drugs were recorded in the
following order: narcotics, depressants, stimulants,
marijuana, and other drugs (National Highway Traffic
Safety Administration 2010b). Prescription opioids fall
under narcotics and are therefore recorded first when
there are multiple drugs. If a drug and its metabolite
were detected, only the parent drug was recorded. Pre-
scription drugs were coded according to the FARS cod-
ing manual and included injectable or oral formulations
of hydrocodone, meperidine, oxycodone, morphine, co-
deine, fentanyl, oxymorphone, propoxyphene, hydromor-
phone, diphenoxylate, methadone, and oxymorphone.
Illegal opioids such as heroin were excluded from the
analysis. Blood alcohol concentrations (BACs) were mea-
sured in grams per deciliter where a BAC of 0.01 g/dl or
greater was considered alcohol-positive. Toxicological
tests for controls were based on oral fluid samples,
first through the enzyme-linked immunosorbent assay
technique to screen for the presence of drugs and if posi-
tive, then through liquid/gas chromatography combined
with mass spectrometry for confirmation (Lacey et al.
2009; National Highway Traffic Safety Administration
2010b; Kelley-Baker et al. 2016). Of the 15,600 drivers in
the control group, 7905 (50.7%) also provided blood sam-
ples for drug testing. For most prescription opioids, the
minimum detection concentration was 20 ng/ml in oral
fluid screening, 25 ng/ml in blood screening and 10 ng/ml
for both oral and blood confirmation (Lacey et al. 2009;
Kelley-Baker et al. 2016). A sample was regarded as posi-
tive if the minimum threshold was attained during the
confirmation test; otherwise it was regarded as negative.
Common prescription opioids detected in controls in-
cluded codeine, morphine, hydrocodone, hydromorphone,
methadone and meperidine. BACs for controls were de-
termined from samples measured using the evidential
breath test device.
Statistical analyses
We estimated odds ratios (ORs) and 95% confidence in-
tervals (95% CIs) through logistic regression modeling.
The potential interaction effect of prescription opioid
use and alcohol use on the risk of fatal crash involve-
ment was assessed using drivers who tested negative for
both prescription opioids and alcohol as the reference
group. Crude ORs and 95% CIs were computed accord-
ing to driver age, sex, geographic region, prescription
opioid testing results and BACs. BAC data were ana-
lyzed as a binary variable (positive if BAC ≥ 0.01 g/dl
and negative if BAC < 0.01 g/dl) as well as a 3-level cat-
egory variable (BAC < 0.01, 0.01–0.07, and ≥ 0.08 g/dl).
Additive interaction was assessed based on three mea-
sures; the relative excessive risk due to interaction
(RERI), the attributable proportion due to interaction
(AP) and the synergy index (S) as follows:
RERI ¼ ORopioidsþalcohol−ORopioids−ORalcohol þ 1





 þ ORalcohol−1ð Þ
 
where RERI = 0, AP =0, and S = 1 denote absence of
interaction on the additive scale. Estimates for RERI, AP,
S and corresponding 95% confidence intervals were
computed using the method of variance estimates recov-
ery (Zou 2008), and the asymptotic approach (Hosmer
and Lemeshow 1992). Estimates for RERI were also
verified using an approach proposed by Knol and Van-
derWeele (2012). In addition, interaction on the multi-
plicative scale was assessed through the prescription
opioids-alcohol interaction term in the multivariable
logistic regression model.
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To assess robustness of our findings, we performed
five sets of sensitivity analyses. First, we included cases
and controls with toxicological testing results from
blood samples only. Second, we restricted the analysis to
cases from 12 states (CA, CO, CT, MA, NH, NY, OH,
PA, RI, VT, WA, WV) that tested more than 80% of
fatally injured drivers during the study period (Brady
and Li 2012). Third, we performed an analysis based on
weighted data for the controls to account for the com-
plex survey design and nonparticipating drivers. Fourth,
we performed a stratification analysis by dividing the
data into two time periods according to the 2007 and
2013–14 NRSs. Finally, we restricted the analysis to
cases that died at the crash scene to minimize the pos-
sible bias introduced by opioid analgesics used after
crashes for trauma care and management. To assess the
extent to which unmeasured confounding might bias the
results, we computed the E-value statistic (VanderWeele
and Ding, 2017). All analyses were performed using SAS
9.4 (SAS Institute Inc., Cary, NC).
Results
Cases included in the study were similar to those eligible
drivers excluded from the analysis due to missing toxico-
logical testing data in crash circumstances, but were youn-
ger (mean age = 38.6 ± 28.4 years vs. 41.9 ± 30.9 years, p <
0.0001), more likely to be male (80.8% vs. 77.9%, p =
0.0034), more likely to have had a license suspension
within the previous 3 years (59.1% vs. 51.9%, p < 0.0001),
and more likely to be involved in nighttime crashes (68.4%
vs. 62.3%, p < 0.0001).
Compared to controls, cases were slightly older, more
likely to be male and were more likely to be from the
Southern or Northeast regions (Table 1). Of the cases,
56.2% tested positive for alcohol and 5.0% positive for
prescription opioids, compared with 7.1 and 3.7% of
controls, respectively (Table 1). Among the cases testing
positive for alcohol, 87.5% had BACs ≥0.08 g/dl, com-
pared with 19.7% of the alcohol-positive controls. On
the bivariable level, significantly increased odds ratios of
fatal crash involvement were associated with older age
(≥ 65 years), male sex, the Southern region, elevated
BACs, and use of prescription opioids (Table 1).
After adjusting for age, sex, region, and BAC level, use
of prescription opioids was associated with a 71% in-
creased risk of fatal crash involvement (adjusted OR =
1.71, 95% CI: 1.37, 2.14) (Table 2). As expected, substan-
tially increased ORs were associated with elevated BACs,
particularly for drivers with BACs ≥0.08 g/dl) (Table 2).
A total of 79 (2.2%) cases and 31 (0.2%) controls tested
positive for both prescription opioids and alcohol. Rela-
tive to drivers who tested negative for both prescription
opioids and alcohol, the estimated odds of fatal crash in-
volvement increased 72% for those testing positive for
prescription opioids and negative for alcohol, nearly
17-fold for those testing negative for prescription opioids
and positive for alcohol, and about 21-fold for that test-
ing positive for both prescription opioids and alcohol
(Table 3). The interaction term indicating concurrent
use of prescription opioids and alcohol was not statisti-
cally significant (χ2(df = 1) = 1.8337, p = 0.1757). None of
the three statistics for measuring interaction on the
additive scale were significant in the unadjusted model
(RERI = 3.63, 95% CI: -5.4, 17.42; AP = 0.14: 95% CI:
-0.34, 0.44; S = 1.18, 95% CI 0.74, 1.86) and in the ad-
justed model (RERI = 3.47, 95% CI: -3.96, 14.50; AP =
0.16: 95% CI: -0.28, 0.43; S = 1.20, 95% CI 0.78, 1.84).
The risk of fatal crash involvement increased with BACs
in parallel between drivers testing negative for prescrip-
tion opioids and those testing positive (Fig. 1).
Results from sensitivity analyses showed significantly
elevated ORs of fatal crash involvement associated with
prescription opioid use when adjusting for alcohol, age,
Table 1 Crude Odds Ratios (ORs) and 95% Confidence Intervals
(CIs) of Fatal Crash Involvement according to Driver
Characteristics in the Continental United States, Selected Time
Periods on Fridays and Saturdays, July 20 through December 1,
2006, 2007, 2008, and June 7, 2012 through March 30, 2013 and
June 7, 2013 through March 30, 2014
Driver
Characteristicsa
Cases, % Controls, % Crude
OR
95% CI
(n = 3606) (n = 15,600)
Age, years
16–24 27.7 28.6 1.04 0.95, 1.14
25–39 32.0 32.6 1.05 1.00, 1.15
40–64 31.3 33.4 1.00 reference
≥ 65 9.0 5.4 1.80 1.56, 2.07
Sex
Female 19.2 40.8 1.00 reference
Male 80.8 59.2 2.90 2.65, 3.17
Region
West 22.2 22.5 1.00 reference
Midwest 22.6 27.9 0.82 0.73, 0.91
Southern 38.4 33.9 1.14 1.04, 1.26
Northeast 16.8 15.7 1.08 0.99, 1.21
Blood alcohol concentration (BAC, g/dl)
<0.01 43.8 92.9 1.00 reference
0.01–0.07 7.0 5.7 2.63 2.27, 3.06
≥ 0.08 49.2 1.4 74.72 64.31, 86.81
Prescription opioids
Negative 95.0 96.3 1.00 reference
Positive 5.0 3.7 1.36 1.14, 1.61
aThere were 52 cases with missing data on blood alcohol concentrations
There were 126 controls with missing data on sex, 297 on age, 7 on blood
alcohol concentrations
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sex, and region. Specifically, the estimated adjusted ORs
were 1.45 (95% CI: 1.12, 1.87) when restricted to blood-
based samples only, 1.68 (95% CI: 1.15, 2.45) when re-
stricted to states that tested 80% or more of fatally in-
jured drivers, 1.78 (95% CI: 1.37, 1.2.31) when weighted
data for controls were used, 1.61 (95% CI: 1.13, 2.31)
when study period was restricted to 2006–2008,1.79
(95% CI: 1.33, 2.47) when study period was restricted to
2012–2014, and 1.89 (95% CI: 1.44, 2.49) when restricted
to cases that died at the crash scene. Results from all
sets of sensitivity analyses indicate the absence of signifi-
cant interaction effects between prescription opioid use
and alcohol on the risk of fatal crash involvement on
either multiplicative or additive scale. The estimated
E-value was 2.83 (95%CI: 2.08,3.58), which would be the
minimum OR of fatal crash involvement associated with
an unmeasured confounding necessary to completely ex-
plain away the association between prescription opioid
use and the risk of fatal crash involvement observed in
this study.
Discussion
Results of this study indicate that prescription opioid
use by drivers is associated with a significantly elevated
risk of fatal crash involvement, independently of alcohol
use. Our results add more evidence to the existent litera-
ture about the effects of prescription opioids on driving
safety (Chihuri and Li 2017b). In light of the increasing
prevalence of prescription opioid use among drivers, our
finding suggests that it is urgent to better understand
and control the impact of the ongoing opioid epidemic
on drugged driving and related injury morbidity and
mortality from motor vehicle crashes.
This study also reaffirms the important role of
alcohol-impaired driving in fatal motor vehicle crashes.
Although we did not find a significant synergistic effect
between prescription opioids and alcohol on fatal crash
risk, concurrent use of these two substances remains
cause of concern as 46.4% of the drivers involved in fatal
motor vehicle crashes who tested positive for prescrip-
tion opioids had elevated BACs. Our results reveal that
the estimated odds of fatal crash involvement for drivers
using both prescription opioids and alcohol are nearly
22 times that for those using neither of the substances.
Driving under the influence of drugs (DUID), such as
marijuana and opiates, is prohibited in all US states and
the District of Columbia. Enforcement of DUID laws,
however, has been hindered by the lack of portable, af-
fordable, and noninvasive technologies for rapid and ac-
curate drug testing and inadequate research evidence
(Government Accountability Office 2015). To reduce the
adverse impact of the opioid epidemic on traffic injuries
and fatalities, it is necessary to increase public awareness
about the hazards of prescription opioids posed to driv-
ing safety through enhanced education programs, par-
ticularly for prescribing clinicians and patients on pain
medications. Current practice guidelines state that pre-
scribing clinicians should start at the lowest possible ef-
fective dosage and use additional caution when initiating
opioids for patients 65 years or older or when increasing
Table 2 Adjusted Odds Ratios (ORs) and 95% Confidence
Intervals (CIs) of Fatal Crash Involvement according to Driver
Characteristics in the Continental United States, Selected Time
Periods on Fridays and Saturdays, July 20 through December 1,
2006, 2007, 2008, and June 7, 2012 through March 30, 2013 and
June 7, 2013 through March 30, 2014
Driver characteristic Adjusted OR 95% CI
Age, years
16–24 0.85 0.74, 0.96
25–39 0.68 0.60, 0.78
40–64 1.00 reference
≥ 65 2.81 2.37, 3.33
Sex
Female 1.00 reference
Male 2.06 1.84, 2.31
Region
West 1.00 reference
Midwest 0.81 0.70, 0.94
Southern 1.06 0.93, 1.21





0.01–0.07 2.59 2.20, 3.06
≥ 0.08 80.09 68.21, 94.04
Prescription opioids
Negative 1.00 reference
Positive 1.71 1.37, 2.14
Table 3 Estimated Odds Ratios (ORs) and 95% Confidence
Intervals (CIs) of Fatal Crash Involvement According to Driver
Prescription Opioid and Alcohol Testing Results in the
Continental United States, Selected Time Periods on Fridays and
Saturdays, July 20 through December 1, 2006, 2007, 2008, June








Negative Negative 1.00 Reference 1.00 Reference
Positive Negative 1.66 1.33, 2.08 1.72 1.37, 2.17
Negative Positive 17.12 15.62, 18.77 17.92 16.19, 19.84
Positive Positive 22.31 1.99, 7.68 21.89 14.38, 33.32
aAdjusted for age, sex and region
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dosages (Centers for Disease Control and Prevention
2016). Before initiation of prescription opioids, clinicians
should discuss all known benefits and risks including po-
tential risk of motor vehicle crashes with their patients.
This is important because approximately 1 in 6 patients
on prescription opioids becomes opioid-dependent
(Alghnam and Castillo 2017) and because driving while
on prescription opioids is a significant risk factor for
fatal motor vehicle crashes.
This study has several limitations. First, data on the
concentration of prescription opioids detected is unavail-
able in the FARS data and therefore we are unable to
assess the dose-response effect and to establish a pos-
sible threshold in morphine milligram equivalents above
which crash risk may increase significantly. Second, test-
ing positive for prescription opioids indicates prescrip-
tion opioid use but not necessarily driving impairment
or crash causation induced by prescription opioids. The
detection window for prescription opioids in blood is
less than 24 h and 1 to 4 days in urine, and the half-life
of opioids is relatively short (less than 4 h) (Smith 2009;
American Institute of Toxicology Laboratories 2011).
Hence, a positive test can be used as an indicator of re-
cent use although we are unable to distinguish whether
the use was legal or not. Third, drug testing results were
unavailable for 46.9% of the eligible cases, which may
introduce selection bias to our results. However, a sensi-
tivity analysis based on cases from 12 states (CA, CO,
CT, MA, NH, NY, OH, PA, RI, VT, WA, WV) that
tested at least 80% of all fatally injured drivers produced
results comparable to our main findings. Fourth, cases
included in the study were more likely than those
excluded to have a license suspension and to be involved
in nighttime crashes, which may lead to overestimation
of the odds ratios. However, the observed association be-
tween prescription opioid use and the risk of fatal crash
involvement is unlikely to be explained by any unmeas-
ured confounding factor given the large E-value (2.83).
Finally, the absence of a significant interaction effect
between prescription opioid use and alcohol use on the
risk of fatal crash involvement should be viewed as a
preliminary finding because our study is likely under-
powered for assessing a modest or small size of the
interaction effect between prescription opioids and alco-
hol on fatal crash risk. Experimental studies have elicited
multiple pathways through which opioids and alcohol
may interact biologically, such as by inhibiting or po-
tentiating common enzyme systems (Bodd et al. 1986;
Meskar et al. 2001; Callahan et al. 2004). Future research
with more refined exposure measurement and larger
sample sizes may help advance our understanding of
opioid-alcohol interaction on driving safety.
Conclusion
Driver use of prescription opioids is associated with a
72% increase in the risk of fatal crash involvement. Al-
though prescription opioids and alcohol do not appear
to confer a significant synergistic effect, concurrent use
of the two substances could increase the risk of fatal
crash involvement by nearly 21-fold. Government re-
sponses to the opioid crisis should include efforts to
understand and reduce drugged driving and related in-
jury morbidity and mortality.
Fig. 1 Estimated Adjusted Odds Ratios of Fatal Crash Involvement According to Blood Alcohol Concentrations and Prescription Opioid Testing Result
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